An Interim Safety Analysis of Combination Stereotactic Ablative Body Radiotherapy (SABR) with Adjuvant Anti-PD1 Immunotherapy in Oligometastatic Renal Cell Carcinoma

被引：0
|
作者：
Siva, Shankar [1 ,2 ,3 ]
Bressel, Mathias [1 ]
Sandhu, Shahneen [1 ]
Tran, Ben [1 ]
Mooi, Jennifer [1 ]
Lewin, Jeremy [1 ]
Loi, Sherene [1 ,2 ,3 ]
Toner, Guy [1 ,2 ,3 ]
Moon, Daniel [1 ]
Goad, Jeremy [1 ]
Shaw, Mark [1 ]
Chander, Sarat [1 ]
Eade, Thomas [4 ]
Guminksi, Alex [4 ]
Dasantha, Jayamanne [4 ]
Pryor, David [5 ]
Cuff, Katherine [5 ]
Wood, Simon [5 ]
Lawrentschuk, Nathan [1 ]
Murphy, Declan [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Northern Sydney Canc Ctr, Sydney, NSW, Australia
[5] Princess Alexandra Hosp, Brisbane, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs19
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [41] Prospective Safety and Feasibility trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)
    All, S.
    de Leon, A. Diaz
    Mohamad, O.
    Choy, H.
    Hammers, H.
    Sanjeevaiah, A.
    Arafat, W.
    Courtney, K.
    Timmerman, R. D.
    Brugarolas, J.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E896 - E897
  • [42] Dosimetric analysis of renal toxicity after stereotactic body radiotherapy for renal cell carcinoma
    Niglas, M.
    Cheung, P.
    Swaminath, A.
    Korol, R.
    Erler, D.
    Vesprini, D.
    Chu, W.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S435 - S435
  • [43] Metastatic Renal Cell Carcinoma Presenting as a Rapidly Enlarging Endotracheal Mass Due to Hyperprogression on Anti-PD1 Immunotherapy
    Hoshal, Steven G.
    Wickwire, Peter C.
    Gandour-Edwards, Regina F.
    Rajappa, Prabhu
    Cates, Daniel J.
    ENT-EAR NOSE & THROAT JOURNAL, 2021, 100 (10_SUPPL) : 905S - 907S
  • [44] I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.
    Chang, Joe Y.
    Lin, Steven H.
    Yao, Luyang
    Gandhi, Saumil
    Liao, Zhongxing X.
    Chun, Stephen G.
    Jeter, Melenda
    Welsh, James William
    Lee, Percy
    Antonoff, Mara
    Feng, Lei
    Lee, J. Jack
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Stereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment?
    Magee, Diana E.
    Wong, Jessica Karen
    Corre, Andres F.
    EUROPEAN UROLOGY, 2022, 82 (06) : 623 - 624
  • [46] Combination of stereotactic ablative radiotherapy with anti-PD-1 in oligoprogressive disease: Final results of a prospective multicenter study
    Zafra, J.
    Sett, R. Chicas
    Rodriguez, D.
    Martinez, J. Castilla
    Salas, B.
    Vera, A.
    Benitez, G.
    Lloret, M.
    Onieva, J. L.
    Barragan, I.
    Lara, P. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1016 - S1017
  • [47] Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study
    Onal, Cem
    Oymak, Ezgi
    Guler, Ozan Cem
    Tilki, Burak
    Yavas, Guler
    Hurmuz, Pervin
    Yavas, Cagdas
    Ozyigit, Gokhan
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (05) : 456 - 464
  • [48] A Delphi consensus study on stereotactic body radiotherapy for oligometastatic renal cell carcinoma (RCC), an ESTRO study - with EAU endorsement
    Marvaso, Giulia
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S142 - S142
  • [49] Bone Only Oligometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Body Radiotherapy: A MULTI-Institutional Study
    Onal, C.
    Guler, O. C.
    Hurmuz, P.
    Yavas, G.
    Tilki, B.
    Oymak, E.
    Yavas, C.
    Ozyigit, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E209 - E209
  • [50] Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study
    Cem Onal
    Ezgi Oymak
    Ozan Cem Guler
    Burak Tilki
    Guler Yavas
    Pervin Hurmuz
    Cagdas Yavas
    Gokhan Ozyigit
    Strahlentherapie und Onkologie, 2023, 199 : 456 - 464
12345